Erste Group Bank Issues Positive Forecast for VRTX Earnings

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) – Equities researchers at Erste Group Bank lifted their FY2027 earnings estimates for Vertex Pharmaceuticals in a report released on Tuesday, March 24th. Erste Group Bank analyst H. Engel now expects that the pharmaceutical company will post earnings per share of $19.48 for the year, up from their previous forecast of $19.31. The consensus estimate for Vertex Pharmaceuticals’ current full-year earnings is $15.63 per share.

A number of other equities research analysts have also recently commented on VRTX. Truist Financial upgraded Vertex Pharmaceuticals to a “strong-buy” rating in a research note on Wednesday. Citigroup boosted their price target on Vertex Pharmaceuticals from $575.00 to $585.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. Cantor Fitzgerald restated an “overweight” rating and set a $590.00 price objective on shares of Vertex Pharmaceuticals in a report on Friday, February 13th. Scotiabank increased their price objective on shares of Vertex Pharmaceuticals from $495.00 to $558.00 and gave the company an “outperform” rating in a research report on Friday, February 13th. Finally, HC Wainwright lifted their target price on shares of Vertex Pharmaceuticals from $591.00 to $641.00 and gave the stock a “buy” rating in a research note on Tuesday, March 10th. One analyst has rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the company. According to data from MarketBeat, Vertex Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $554.30.

Vertex Pharmaceuticals Price Performance

Shares of VRTX stock opened at $454.97 on Thursday. The stock’s fifty day moving average price is $468.97 and its 200 day moving average price is $441.56. Vertex Pharmaceuticals has a 1-year low of $362.50 and a 1-year high of $510.77. The company has a market cap of $115.58 billion, a price-to-earnings ratio of 29.68, a price-to-earnings-growth ratio of 1.92 and a beta of 0.31.

Vertex Pharmaceuticals (NASDAQ:VRTX) last issued its quarterly earnings results on Thursday, February 12th. The pharmaceutical company reported $5.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.05 by ($0.02). Vertex Pharmaceuticals had a return on equity of 24.30% and a net margin of 32.94%.The business had revenue of $3.19 billion for the quarter, compared to analyst estimates of $3.18 billion. During the same period in the previous year, the company posted $3.98 earnings per share. The business’s revenue for the quarter was up 9.5% on a year-over-year basis.

Hedge Funds Weigh In On Vertex Pharmaceuticals

A number of institutional investors have recently bought and sold shares of VRTX. Motiv8 Investments LLC purchased a new stake in shares of Vertex Pharmaceuticals in the 4th quarter valued at $26,000. Swiss RE Ltd. purchased a new position in shares of Vertex Pharmaceuticals during the fourth quarter worth $28,000. Chesapeake Asset Management LLC raised its holdings in shares of Vertex Pharmaceuticals by 110.0% during the third quarter. Chesapeake Asset Management LLC now owns 63 shares of the pharmaceutical company’s stock worth $25,000 after purchasing an additional 33 shares during the last quarter. Eagle Bay Advisors LLC acquired a new position in Vertex Pharmaceuticals during the fourth quarter valued at $29,000. Finally, IMG Wealth Management Inc. lifted its position in Vertex Pharmaceuticals by 277.8% during the fourth quarter. IMG Wealth Management Inc. now owns 68 shares of the pharmaceutical company’s stock valued at $31,000 after purchasing an additional 50 shares during the period. 90.96% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Vertex Pharmaceuticals

In other Vertex Pharmaceuticals news, EVP Duncan Mckechnie sold 4,910 shares of the business’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $487.65, for a total transaction of $2,394,361.50. Following the sale, the executive vice president owned 17,559 shares in the company, valued at approximately $8,562,646.35. The trade was a 21.85% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP Amit Sachdev sold 1,846 shares of the firm’s stock in a transaction dated Wednesday, February 25th. The stock was sold at an average price of $486.35, for a total value of $897,802.10. Following the completion of the transaction, the executive vice president owned 55,570 shares of the company’s stock, valued at approximately $27,026,469.50. The trade was a 3.22% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders have sold 93,485 shares of company stock worth $43,967,586. 0.20% of the stock is owned by corporate insiders.

Key Stories Impacting Vertex Pharmaceuticals

Here are the key news stories impacting Vertex Pharmaceuticals this week:

• Positive Sentiment: Truist raised its price target on Vertex to $525 (from $490) and kept a Buy rating after encouraging Week‑36 interim results from Vertex’s Phase 3 RAINIER study — a clear positive catalyst supporting higher upside expectations. Truist Raises Vertex (VRTX) Price Target Following Phase 3 Trial Results
• Positive Sentiment: Multiple bullish writeups and retail/investor attention argue VRTX remains a buy—analysts and commentators point to durable CFTR franchise cash flows, pipeline upside and the recent dip as a potential buying opportunity. Is Vertex Pharmaceuticals Incorporated (VRTX) A Good Stock To Buy Now?
• Neutral Sentiment: Zacks and market headlines note VRTX outperformed the broader market in the latest session and is drawing elevated attention from Zacks users — this likely amplified buying interest but is descriptive rather than a fresh fundamental shift. Vertex Pharmaceuticals (VRTX) Laps the Stock Market: Here’s Why
• Neutral Sentiment: Reports of large short‑interest changes are inconsistent/placeholder in recent feeds (reported zeros/NaN), so there’s no clear short‑squeeze signal — effectively neutral on near‑term price pressure.
• Negative Sentiment: Competition risk: Maze Therapeutics reported positive Phase II data for an APOL1‑mediated kidney disease drug that targets the same pathway Vertex is pursuing — the news highlights competitive risk to Vertex’s AMKD franchise, which could weigh on long‑term upside if competitors advance. Maze tumbles despite positive data for kidney disease drug

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Inc is a Boston-based biotechnology company focused on the discovery, development and commercialization of therapies for serious diseases. Founded in 1989, Vertex built its reputation on research-driven drug development and is best known for its work in cystic fibrosis (CF), where its portfolio of small-molecule CFTR modulators transformed standards of care for many people with the disease. The company operates research and development, manufacturing and commercial organizations and serves patients and healthcare systems in multiple international markets.

Vertex’s marketed products center on CFTR modulators that target the underlying cause of cystic fibrosis rather than just treating symptoms.